Results 121 to 130 of about 5,013 (195)

Evaluation of Efficacy of Adding Aprepitant to Palonosetron and Dexamethasone in Carboplatin and Etoposide Therapy

Tatsuhiko Sakamoto, Moeko Kado, Yoshitaka Saito, Kazuki Uchiyama, Ryota Kanno, Osamu TANIGUCHI, Yoh Takekuma, Jun Sakakibara‐Konishi, Yasushi Shimizu, Ichiro Kinoshita, Mitsuru Sugawara   +10 more
openalex   +2 more sources

Palonosetron might not attenuate spinal anesthesia-induced hypotension during orthopedic surgery

, 2016
Jung Ju Choi, Young Jin Chang, Wol Seon Jung, Youn Yi Jo   +3 more
openalex   +1 more source

STOP-CINV Study: Safety and Efficacy of IV Akynzeo® (Fosnetupitant 235 mg and Palonosetron 0.25 mg) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Indian Patients. [PDF]

Cureus
Shukla P, Valame S, Nanda S, Shakya NK, Verma AK, Hanji A, Pednekar A, Bhagat S, Patil S, Petare AU, Bhushan S, Barkate H.   +11 more
europepmc   +1 more source

Aprepitant use during chemotherapy and association with survival in women with early breast cancer. [PDF]

J Natl Cancer Inst
Botteri E, Hjorth S, Conforti F, Bagnardi V, Andreassen BK, Støer NC, Bhargava S, Ursin G, Gandini S, Sloan EK, Chang A.   +10 more
europepmc   +1 more source

Effects of the 5-Hydroxytryptamine 3 Receptor Antagonist Palonosetron on Hemostasis: An In Vitro Study Using Thromboelastography. [PDF]

Medicina (Kaunas)
Shin HJ, Koo BW, Kim JN, Park JI, Na HS.
europepmc   +1 more source

Comparative Study of Lidocaine and Palonosetron Pretreatment in Reduction of Propofol Induced Injection Pain

, 2018
Suruchi Ambasta, Swagat Mahapatra
openalex   +1 more source

Fosaprepitant for the prevention of multiple-day cisplatin chemotherapy-induced nausea and vomiting: a prospective randomized controlled study. [PDF]

BMC Pharmacol Toxicol
Wang L, Jin G, Wang W, Zhao J, Chen F, Li X, Jiang Y, Zhang Z, Li Q.   +8 more
europepmc   +1 more source

Prolonged inhibition of 5‐HT₃ receptors by palonosetron results from surface receptor inhibition rather than inducing receptor internalization

, 2013
Joanne Hothersall, Christopher Moffat, Christopher N. Connolly   +2 more
openalex   +2 more sources

Omission of dexamethasone in prophylaxis for highly emetogenic chemotherapy in patients with breast cancer. [PDF]

Einstein (Sao Paulo)
Rebouças CV, Alves RB, Yamada AMTD, Del Giglio A, Cruz FJSM.   +4 more
europepmc   +1 more source

Individual patient data meta-analysis of NEPA versus aprepitant-based antiemetic regimens for preventing chemotherapy-induced nausea and vomiting. [PDF]

Future Oncol
Navari RM, Tyler T, Inui N, Iihara H, Bonizzoni E, Park YH, Rugo HS, Roeland EJ.   +7 more
europepmc   +1 more source